Pfizer on Tuesday reported fourth-quarter results that topped estimates even amid dwindling demand for its Covid products, while reaffirming its modest 2026 guidance that rattled investors in December. The pharmaceutical giant is looking to longer-term investments in its pipeline, including its $10 billion acquisition of the obesity biotech Metsera , to counter waning Covid product sales and declines from older drugs. Pfizer moved to show the promise of that investment Tuesday, when it also

Tag-uri: Pfizer Coronavirus